PK/PD in the Process of Anti-Infective Drug Registration: A Present View from the US regulatory agency (Pharmacological Aspects)

30/07/99

Click here to start

Table of Contents

PK/PD in the Process of Anti-Infective Drug Registration: A Present View

Agency’s Charge - Prof. P. Tulkens (ISAP)

Recent Meetings Involving Agency Discussion of PK/PD of Anti-Infectives 

Recent Meetings Involving Agency Discussion of PK/PD of Anti-Infectives (cont.)

DRAFT Guidance Documents for Industry - Developing Antimicrobial Drugs: General Considerations for Clinical Trials and Individual Indications 

July 1998 DAIDP Advisory Committee DRAFT Guidance Documents for Industry - Developing Antimicrobial Drugs: General Considerations for Clinical Trials and Individual Indications 

July 1998 DAIDP Advisory Committee (cont.)

October 1998 DAIDP Advisory Committee Development of Drugs for Resistant Bacteria, Including Selective Spectrum Agents

October 1998 DAIDP Advisory Committee (cont.)

October 1998 DAIDP Advisory Committee (cont.)

October 1998 DAIDP Advisory Committee (cont.)

March 1999 FDA/ISAP Workshop Pharmacodynamics and the Impact on Anti-Infective and Anti-Viral Drug Development

March 1999 FDA/ISAP Workshop (cont.)

March 1999 FDA/ISAP Workshop (cont.)

March 1999 FDA/ISAP Workshop (cont.)

March 1999 FDA/ISAP Workshop (cont.)

March 1999 FDA/ISAP Workshop (cont.)

March 1999 FDA/ISAP Workshop (cont.)

FDA Review Division Organization

Author: Colangelo 

Email: webmaster@isap.org

Home Page: http://www.isap.org/Birmingham-1999.htm